Last reviewed 2026-04-20 · How we verify

Radicava

At a glance

Approved indications

• Amyotrophic lateral sclerosis
• Ischemic stroke

Common side effects

• Contusion
• Gait disturbance
• Headache
• Dermatitis
• Eczema
• Fatigue
• Respiratory failure, respiratory disorder, hypoxia
• Glycosuria
• Tinea infection

Serious adverse events

• Anaphylaxis
• Hypersensitivity reactions
• Sulfite allergic reactions

Key clinical trials

• A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects (PHASE1)
• Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids (PHASE2)
• Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study (PHASE4)
• Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment (PHASE1)
• PK Study in Subjects With Severe Hepatic Impairment (PHASE1)
• Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke (PHASE2)
• Dose Finding Study of MCI-186 in Acute Ischemic Stroke (PHASE2)
• Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Radicava CI brief — competitive landscape report
• Radicava updates RSS · CI watch RSS
• Shanghai Auzone Biological Technology Co., Ltd. portfolio CI